MetaVia's Obesity Drug Hits Key Dosing Milestone; Q2 R&D Spend Jumps 52%
MTVA sits 50% above its 52-week low of $0.966.
Summary
MetaVia's Q2 update brings two concrete developments: all patients in the Phase 1 Part 3 study of obesity drug DA-1726 successfully reached the highest planned doses (48 mg and 64 mg), and 16-week topline data is now expected in Q4 2026. This follows the positive 8-week data in June showing up to 9.1% weight loss, and the dose escalation milestone de-risks the ongoing trial. R&D expenses rose to $3.5M from $2.3M a year ago, reflecting increased spending on DA-1726 development, and the net loss widened due to the higher R&D spending. The company also plans an End-of-Phase 2 meeting with the FDA for vanoglipel in the second half of 2026. With a market cap under $10M, the clinical progress is material, but the financial update shows continued cash burn without new financing details.
At the time of this announcement, MTVA was trading at $1.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.5M. The 52-week trading range was $0.97 to $19.03. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: PR Newswire.